Overview

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2017-03-08

Target enrollment:
0

Participant gender:
All

Summary

This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza®) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Liraglutide

Criteria

Inclusion Criteria:

- Subjects with T2DM (Type 2 Diabetes Mellitus), including newly-diagnosed subjects, who
require treatment with Victoza® according to the clinical judgment of their treating
physician

- Subjects (and/or parents or the subject's legally acceptable representative) who are
capable of giving study-specific signed informed consent before any collection of
information

Exclusion Criteria:

- Subjects with a hypersensitivity to Victoza® or to any of the excipients

- Subjects who are pregnant, breast feeding or have the intention of becoming pregnant
within the study periods

- Subjects with personal or family history of medullary thyroid carcinoma (MTC)

- Subjects with multiple endocrine neoplasia syndrome type 2 (MEN2)